Ransom C, Zamora G, Jones L
Pharmaco LSR, Incorporated, Austin, Texas 78704, USA.
Qual Assur. 1995 Mar;4(1):80-2.
As a quality assurance (QA) department for a clinical research organization, QA conducts audit activities for clinical trials managed by our organization and acts as an independent QA group for several other companies. A quality assurance/regulatory compliance Master Audit Plan is developed for each study or each audit if the audit is an independent task. The Master Audit Plan designed for a specific clinical study consists of a combination of several QA activities designed to ensure quality and regulatory compliance, to define timelines, and to identify personnel. These activities may include the review of the regulatory documents for each investigative site prior to the shipping of test article (test article release), review of informed consent, review of internal sponsor study files, and clinical site audits. Results of audit activities conducted under the Master Audit Plan for several clinical studies have been compiled for three of the major QA tasks. These include test article release, informed consent review, and site audits. A review of regulatory document files for test article release indicated that 13% required additional documents or correction of submitted documents. A review of informed consents found that 32% required revision. Site audit activities indicated that the clinical sites were, in general, adhering to Federal regulations and GCP guidelines. Observations noted at sites tended to fall into the categories of test article accountability issues, regulatory document additions or revisions, and quality control issues.
作为一家临床研究机构的质量保证(QA)部门,QA对本机构管理的临床试验开展审计活动,并作为其他几家公司的独立QA团队。针对每项研究或每次审计(若审计为独立任务)制定质量保证/法规合规主审计计划。为特定临床研究设计的主审计计划由多项QA活动组合而成,旨在确保质量和法规合规、确定时间线并明确人员。这些活动可能包括在试验用药品发运前审查各研究站点的法规文件(试验用药品放行)、审查知情同意书、审查申办方内部研究档案以及临床站点审计。已针对三项主要QA任务汇总了根据多项临床研究的主审计计划开展的审计活动结果。这些任务包括试验用药品放行、知情同意书审查和站点审计。对试验用药品放行的法规文件档案审查表明,13%需要补充文件或对提交的文件进行修正。对知情同意书的审查发现,32%需要修订。站点审计活动表明,临床站点总体上遵守联邦法规和GCP指南。在站点发现的问题往往属于试验用药品管理责任问题、法规文件补充或修订以及质量控制问题。